Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3

Abstract excerpt

Abstract Background and purpose Clinical trials in spinocerebellar ataxia type 3 (SCA3) will require biomarkers for use as outcome measures. Methods To evaluate total tau (t‐tau), glial fibrillary acidic protein (GFAP), ubiquitin carboxy‐terminal hydrolase L1 (UCHL1) and neurofilament light‐chain (NfL) as fluid biomarkers in SCA3, ATXN3 mutation carriers (n = 143) and controls (n = 172) were clinically assessed,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Amyotrophic Lateral Sclerosis Research
• Share to Genetic Neurodegenerative Diseases
• Share to Glycogen Storage Diseases and Myoclonus